Universities decry Biden's plan for 'march-in' rights as disincentivizing biopharma partnerships
A group of nonprofits representing major academic institutions and medical schools has come out against President Joe Biden’s new framework to use “march-in” rights to reduce the price of some medicines developed with federal funds.
Echoing comments from industry groups like PhRMA, the associations and nonprofits argued that the framework from December increases uncertainty around when march-in rights might be considered, “which will have a detrimental and destabilizing effect on university and medical school technology transfer efforts and planning.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.